Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Datroway (datopotamab deruxtecan) approved in China for patients with previously treated metastatic HR positive, HER2 negative breast cancer – Daiichi Sankyo

Written by | 24 Sep 2025

Datroway (datopotamab deruxtecan) has been approved in China for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+… read more.

Datroway (datopotamab deruxtecan) is approved in Japan as the first TROP-2 directed therapy for patients with HR positive, HER2 negative breast cancer – Daiichi Sankyo

Written by | 30 Jun 2025

Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or… read more.

Datroway approved in the U.S. for patients with previously treated metastatic HR Positive, HER2 negative breast cancer – Daiichi Sankyo

Written by | 31 Jan 2025

Datroway  (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.